<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202005</url>
  </required_header>
  <id_info>
    <org_study_id>NEVIR5U14EU</org_study_id>
    <secondary_id>2014-002247-18</secondary_id>
    <nct_id>NCT02202005</nct_id>
  </id_info>
  <brief_title>Multiple Dose BE Study With Nevirapine 400mg PR Tablets</brief_title>
  <official_title>A Multiple Dose, Open Label, Pivotal, 4 Period, 2 Treatment, Sequence Full Replicative Crossover Study to Assess the Bioequivalence (BE) of TEVA's Generic Once Daily Nevirapine 400 mg Prolonged Release (PR) Formulation Compared With the Approved Reference Product Viramune® 400 mg Prolonged Release Tablets Under Fasted Conditions in HIV1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ratiopharm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this steady state pivotal study is to compare the rate and extent of&#xD;
      absorption and to evaluate Bioequivalence of test drug compared to the approved reference&#xD;
      product in HIV infected individuals&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations by AUC0 τ,ss (area under the concentration time curve)</measure>
    <time_frame>Days 14, 28, 42, 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cτ,ss (defined as concentration at the end of dosing interval)</measure>
    <time_frame>Days 14, 28, 42, 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum observed plasma concentration)</measure>
    <time_frame>Days 14, 28, 42, 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of fluctuation over one dosing interval at steady state (Fl(%)</measure>
    <time_frame>Days 14, 28, 42, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss (the time to maximum plasma concentration at steady state)</measure>
    <time_frame>Days 14, 28, 42, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum plasma concentration at steady state)</measure>
    <time_frame>Days 14, 28, 42, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma drug concentration</measure>
    <time_frame>Days 14, 28, 42, 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Viramune®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Nevirapine 400mg PR tablet</description>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_label>Viramune®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viramune®</intervention_name>
    <description>Viramune® 400 mg Retardtabletten</description>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_label>Viramune®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated written informed consent prior to admission to the study&#xD;
&#xD;
          2. HIV1 infected males or females of 18 to 65 years, nonsmoker (use of cannabis may be&#xD;
             accepted)&#xD;
&#xD;
          3. Body weight ≥ 50.0 kg and BMI ≥ 18.0 and ≤ 32.0 kg/m2&#xD;
&#xD;
          4. Absence of clinically significant history of neurological, endocrinal, cardiovascular,&#xD;
             pulmonary, haematological, psychiatric, gastrointestinal, renal, hepatic, obstructive&#xD;
             disorders, cholestasis, and metabolic disease&#xD;
&#xD;
          5. Treatment with a stable nevirapine based combination regimen for at least the&#xD;
             preceding 12 weeks (or 6 weeks if switched from an antiretroviral regimen containing&#xD;
             two nucleoside analogues and efavirenz)&#xD;
&#xD;
          6. Background HIV therapy with a stable antiretroviral regimen that is recommended in&#xD;
             combination with nevirapine according to British HIV Association clinical guidelines:&#xD;
&#xD;
               1. Abacavir and lamivudine {ABC/3TC} as fixed dose combination Kivexa&#xD;
&#xD;
               2. Tenofovir and emtricitabine {TDF/FTC} Truvada&#xD;
&#xD;
               3. Zidovudine and lamivudine {AZT/3TC} - Combivir, OR&#xD;
&#xD;
               4. Tenofovir and lamivudine as separately prescribed components and kept constant&#xD;
                  (in combination and dosage) throughout the whole course of the study&#xD;
&#xD;
          7. An HIV viral load &lt; 50 copies/mL in preceding 3 months and at screening&#xD;
&#xD;
          8. A CD4+ Tcell count &gt; 50 cell/mm3&#xD;
&#xD;
          9. Acceptable screening laboratory values that indicate adequate baseline organ function&#xD;
&#xD;
         10. Willingness to abstain from ingesting medications that are listed as contraindicated&#xD;
             for nevirapine during the whole course of the study&#xD;
&#xD;
         11. Capable of completing patient diaries&#xD;
&#xD;
         12. Capable and willing to come back for PK assessments and follow up&#xD;
&#xD;
         13. Willingness to refrain from excessive physical activity during the trial&#xD;
&#xD;
         14. Willingness of male study participants to not father a child during and throughout the&#xD;
             study. To prevent a pregnancy of the female partner, both the male study participant&#xD;
             and the female partner need to take appropriate contraceptives to prevent pregnancy&#xD;
             during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infection with HIV2 or HIV1 group O.&#xD;
&#xD;
          2. Current treatment with an HIV protease inhibitor&#xD;
&#xD;
          3. Participation in any other study within 30 days of Day 1, or intention to participate&#xD;
             in another study during participation in this study.&#xD;
&#xD;
          4. Male and female patients who are not willing to use male or female condoms to prevent&#xD;
             HIV transmission&#xD;
&#xD;
          5. Female patients of childbearing potential who:&#xD;
&#xD;
               1. Have a positive serum pregnancy test at screening.&#xD;
&#xD;
               2. Are breast feeding.&#xD;
&#xD;
               3. Are planning to become pregnant&#xD;
&#xD;
               4. Are not willing to take appropriate measures to prevent pregnancy during the&#xD;
                  study&#xD;
&#xD;
          6. Females who do not use an acceptable contraceptive regimen or confirm total abstinence&#xD;
             will be allowed to participate in this study only if they are not considered to be of&#xD;
             childbearing potential&#xD;
&#xD;
          7. Laboratory parameters &gt; DAIDS grade 2 Coagulation&#xD;
&#xD;
          8. Laboratory parameters &gt; DAIDS grade 2 Total triglycerides&#xD;
&#xD;
          9. Hypersensitivity to the active substance or any ingredients of the test or reference&#xD;
             investigational products or chemically related compounds.&#xD;
&#xD;
         10. Contraindication to Nevirapine&#xD;
&#xD;
         11. Relevant history or current condition, illness that might interfere with drug&#xD;
             absorption, distribution, metabolism or excretion&#xD;
&#xD;
         12. Use of concomitant medication (other than the stable background antiretroviral HIV&#xD;
             therapy) that may interfere with the pharmacokinetics of nevirapine and/or the&#xD;
             background antiretroviral HIV therapy)&#xD;
&#xD;
         13. Intake of products containing St. John's Wort from 14 days before treatment with study&#xD;
             medication (Day 1) and not willing to abstain from it throughout the study until after&#xD;
             the last study visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea and Westminster NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelsea and Westminster NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

